Trials / Active Not Recruiting
Active Not RecruitingNCT05290597
A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, open-label, multicenter, dose-escalation study designed to evaluate the safety, tolerability, and DLTs to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD), and the RP2D of sequential doses of IBI363 (study drug) in subjects with advanced, refractory solid malignancies or lymphomas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IBI363 | a mutated IL-2 cytokine fused to an anti-PD-1 antibody to combine IL-2 pathway stimulation with checkpoint blockade. |
Timeline
- Start date
- 2022-08-22
- Primary completion
- 2026-01-28
- Completion
- 2026-12-31
- First posted
- 2022-03-22
- Last updated
- 2026-03-05
Locations
4 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT05290597. Inclusion in this directory is not an endorsement.